NASDAQ:AKTX Akari Therapeutics Q2 2026 Earnings Report $9.30 -1.36 (-12.76%) Closing price 04:00 PM EasternExtended Trading$9.51 +0.21 (+2.26%) As of 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Akari Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$1.39Beat/MissN/AOne Year Ago EPSN/AAkari Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAkari Therapeutics Announcement DetailsQuarterQ2 2026Date8/18/2026TimeBefore Market OpensConference Call DateTuesday, August 18, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Akari Therapeutics Earnings HeadlinesAkari Therapeutics Enters Strategic Research Collaboration with Whitehawk TherapeuticsJuly 21 at 7:05 AM | globenewswire.comAkari Therapeutics PLC (NASDAQ:AKTX) Short Interest Down 60.1% in JuneJuly 13, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.July 21 at 1:00 AM | InvestorPlace (Ad)Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory BoardJuly 7, 2026 | globenewswire.comAkari Shareholders Approve Warrant Exercises and Share IssuancesJune 29, 2026 | theglobeandmail.comAkari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory MilestonesJune 29, 2026 | globenewswire.comSee More Akari Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Akari Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akari Therapeutics and other key companies, straight to your email. Email Address About Akari TherapeuticsAkari Therapeutics (NASDAQ:AKTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders. Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease. In addition, the company is advancing coversin, a small‐protein C5 inhibitor with potential applications in ophthalmology and hematology. These programs leverage Akari’s proprietary platform chemistry to achieve high specificity and subcutaneous dosing convenience. Headquartered in London, United Kingdom, with research and development operations in the United States, Akari Therapeutics was founded to translate cutting-edge complement science into first-in-class medicines. The company is led by an experienced management team with deep expertise in immunology, drug development and regulatory affairs, and it collaborates with academic institutions and patient organizations to support global clinical studies and future commercialization efforts. View Akari Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3M's Redemption Arc: Can Q2 Earnings Change the Narrative?Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of EarningsConfidence Is Back, But Earnings Show the Consumer Is Being PickyIndustrial and Utility Giants Boost Dividends as Data Center Tailwinds BuildIREN’s $2.8 Billion AI Contract Haul Changes the Stock’s StoryBuy, Hold, or Wait: 3 Small-Cap Stocks Telling Different StoriesIs Domino's Stock Serving Up a Buying Opportunity? Upcoming Earnings Tesla (7/22/2026)Freeport-McMoRan (7/22/2026)Alphabet (7/22/2026)International Business Machines (7/22/2026)ServiceNow (7/22/2026)AT&T (7/22/2026)TE Connectivity (7/22/2026)Texas Instruments (7/22/2026)United Rentals (7/22/2026)Philip Morris International (7/22/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
